Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials

Abstract

Background

This study investigated the clinical efficacy sofosbuvir/daclatasvir (SOF-DCV) in patients with COVID-19.

Research design and methods

PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for relevant articles written before January 6, 2022. Only randomized controlled trials (RCTs) comparing the clinical efficacy of SOF-DCV (study group) with alternative treatments (control group) in patients with COVID-19 were included.

Results

A total of 9 RCTs were included. The all-cause mortality rate in the study group was 10.7% (96/898), which was lower than that in the control group (12.3%, 108/871). However, this difference was not statistically significant (odds ratio [OR] = 0.83; 95% CI, 0.62–1.12; I² = 49%). The overall clinical recovery rate was significantly higher in the study group than in the control group (OR = 2.34; 95% CI, 1.47–3.72; I² = 20%). Furthermore, the average length of hospital stay was shorter in the study group than in the control group (mean deviation = −1.84; 95% CI, −3.42 to −0.26, I² = 68%).

Conclusions

Although SOF-DCV did not confer a survival benefit in patients with COVID-19, it may increase a patient’s odds of clinical recovery, and shorten the length of their hospital stay.

KEYWORDS:

• COVID-19
• intensive care unit
• mechanical ventilation
• mortality
• sofosbuvir/daclatasvir

Author contributions

Conception: C-K Chen, J-H Kao, and C-M Chao; study design: C-K Chen, T-S Weng and Y-H Chen; analysis and interpretation: T-S Weng, Y-H Chen and J-H Kao; drafting or writing: C-K Chen and C-M Chao; and substantial revision or critical review: J-H Kao and C-M Chao. All authors have agreed on the journal to which the article will be submitted; have reviewed the article; and have agreed on all versions of the article before submission, during revision, and during submission for publication and any significant changes introduced at the proofing stage. In addition, all authors agree to take responsibility for the content of the article and to resolve any questions raised about the accuracy or integrity of the published work.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed here

Additional information

Funding

This paper was not funded.